Tradegate
07.11.25 | 11:27
0,051 Euro
-10,53 % -0,006
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,048 | 0,067 | 07.11. | |
| 0,054 | 0,060 | 07.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Hemostemix Inc (2): Hemostemix closes $461,230 first tranche of financing | 3 | Stockwatch | ||
| Di | Hemostemix Inc.: Hemostemix Closes Private Placement of $461,230 | 328 | Newsfile | Calgary, Alberta--(Newsfile Corp. - November 4, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy... ► Artikel lesen | |
| 31.10. | Hemostemix Inc (2): Hemostemix talks work in Florida | 2 | Stockwatch | ||
| 30.10. | Hemostemix Inc.: Hemostemix's Boots on the Ground in Florida October Update | 348 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 30, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| HEMOSTEMIX Aktie jetzt für 0€ handeln | |||||
| 28.10. | Hemostemix Inc.: Hemostemix Announces Its Webinar for Florida Vascular Surgeons: Autologous Stem Cell Therapy for CLTI | 337 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 28, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 23.10. | Hemostemix Inc (2): Hemostemix receives Know Your Health trademark in Japan | 3 | Stockwatch | ||
| 22.10. | Hemostemix Inc.: Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42 | 304 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 16.10. | Hemostemix Inc (2): Hemostemix seeks to treat refractory angina | 3 | Stockwatch | ||
| 15.10. | Hemostemix Inc.: Hemostemix Adds the Treatment of Refractory Angina to Its Phase 1 Basket Protocol | 310 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 15, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 10.10. | Hemostemix Inc (2): Hemostemix applies for vascular dementia study approval | 4 | Stockwatch | ||
| 09.10. | Hemostemix Inc.: Hemostemix Files for Ethics Approval of its Study of Vascular Dementia | 311 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 9, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has filed its Institutional Review... ► Artikel lesen | |
| 08.10. | Hemostemix Inc (2): Hemostemix receives $330,000 lead order for placement | 2 | Stockwatch | ||
| 07.10. | Hemostemix Inc.: Hemostemix's Insider Lead Order of $330,000 Private Placement | 292 | Newsfile | Calgary, Alberta--(Newsfile Corp. - October 7, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce a lead order of $330,000 for a non brokered... ► Artikel lesen | |
| 24.09. | Hemostemix Inc (2): Hemostemix files FDA trial for ACP-01 stem therapy | 2 | Stockwatch | ||
| 23.09. | Hemostemix Inc.: Hemostemix Files FDA Submission for Basket Protocol (Filing 1517) to Advance ACP-01 (VesCell) Across Multiple Ischemic and Vascular Indications Simultaneously | 358 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 17.09. | Hemostemix Inc.: Hemostemix to Present at Life Science Investor Forum | 178 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 16.09. | Hemostemix Inc.: Hemostemix to Present Its Clinical Data of the Treatment of Severe Angina | 357 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 16, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 12.09. | Hemostemix Inc (2): Hemostemix two million shares for debt | 2 | Stockwatch | ||
| 11.09. | Hemostemix Inc (2): Hemostemix to issue two million shares for debt | 2 | Stockwatch | ||
| 10.09. | Hemostemix Inc.: Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share | 448 | Newsfile | Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous (patient's own) stem cell therapy company offering... ► Artikel lesen |
1 2 3 4 5 Weiter >>
95 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,236 | -10,00 % | EQS-News: Evotec SE: In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über 650 Mio. US$ zuzüglich Umsatzbeteiligungen | EQS-News: Evotec SE
/ Schlagwort(e): Vereinbarung
In einer wegweisenden Transaktion unterzeichnet Evotec eine Vereinbarung mit Sandoz über potenzielle Zahlungen in Höhe von über... ► Artikel lesen | |
| QIAGEN | 37,335 | -0,05 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN zahlt rund USD 500 Millionen durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Aktienrückkauf
QIAGEN N.V.: QIAGEN zahlt rund USD 500 Millionen durch einen synthetischen Aktienrückkauf an seine Aktionärinnen und Aktionäre zurück... ► Artikel lesen | |
| VALNEVA | 3,690 | -0,27 % | Valneva: Neue klinische Daten zum Zika-Impfstoff VLA1601 | Valneva hat positive Ergebnisse einer Phase-1-Studie zu seinem zweiten Zika-Impfstoffkandidaten VLA1601 gemeldet. In der Untersuchung mit rund 150 Teilnehmern im Alter von 18 bis 49 Jahren wurde der... ► Artikel lesen | |
| EPIGENOMICS | 0,890 | 0,00 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 6,459 | +0,19 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 307,10 | -0,26 % | Stryker stock price target lowered to $450 from $455 at Bernstein | ||
| CRISPR THERAPEUTICS | 46,800 | -1,68 % | Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings? | ||
| CORE ONE LABS | 0,079 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| OCUGEN | 1,162 | -0,85 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,180 | -1,46 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 69,82 | +0,06 % | Chardan Capital downgrades Avidity Biosciences stock on Novartis acquisition | ||
| RECURSION PHARMACEUTICALS | 4,630 | +0,22 % | Recursion Pharmaceuticals: Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update | Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells-the second neuro map designed to accelerate treatments for a wide range of neurological... ► Artikel lesen | |
| MBX BIOSCIENCES | 25,570 | +3,40 % | MBX Biosciences, Inc.: MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | Reported positive topline results from the Phase 2 Avail trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering, raising approximately $200 million in gross... ► Artikel lesen | |
| BIONTECH | 89,05 | -0,22 % | Biontech öffnet seine Bücher | MAINZ (dpa-AFX) - Nach der Verkündung mehrerer größerer Deals wird das Pharmaunternehmen Biontech an diesem Montag frische Geschäftszahlen vorlegen. Äußern dürften sich die Mainzer bei der Vorlage... ► Artikel lesen | |
| DISC MEDICINE | 83,85 | -3,62 % | Disc Medicine Inc: Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update | Submitted a New Drug Application (NDA) for accelerated approval of bitopertin in erythropoietic protoporphyria (EPP) on September 29, 2025; Awarded the FDA Commissioner's National Priority Voucher... ► Artikel lesen |
Das Unternehmen HEMOSTEMIX INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -10,53 % bei einem Aktienkurs von 0,051 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOSTEMIX INC finden Sie auf Wallstreet Online.